Updates in ACS Management: Applying Clinical Trial Data and Guideline Recommendations to Individualize Duration of Dual Antiplatelet Therapy
June 15, 2018
June 15, 2019
Scroll to the Bottom of this Information to Begin this Course
Supported by an educational grant from AstraZeneca.
- Physicians (ACCME) — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Pharmacists (ACPE) — 1.0 contact hours
- Nurses (ANCC) — 1.0 contact hours
All other health care professionals completing this course will be issued a statement of participation.
Cardiologists, internal medicine physicians, emergency department physicians, residents/fellows, physician assistants, nurse practitioners, registered nurses, pharmacists, and other healthcare professionals involved in the management of patients with acute coronary syndrome.
The goal of this activity is to provide clinicians with an update on recent changes to evidence-based guideline recommendations related to optimal antiplatelet therapy management in acute coronary syndrome (ACS). Expert faculty will review recent clinical trial data and ACC/AHA guideline updates to help practicing clinicians individualize the duration of dual antiplatelet therapy (DAPT), based on patient specific characteristics and explore strategies members of the healthcare team can employ to improve patient adherence to DAPT.
At the conclusion of this activity, participants will be able to:
- Examine recent clinical data and ACC/AHA guideline updates regarding the optimal use and duration of dual antiplatelet therapy (DAPT) in acute coronary syndromes (ACS).
- Individualize the duration of DAPT following ACS or percutaneous coronary intervention (PCI) by examining patient specific factors to balance ischemic vs. bleeding risk of extended DAPT
- Explore strategies members of the interprofessional healthcare team can employ to improve adherence and long-term persistence to antiplatelet therapies at discharge and beyond.
Tracy Y. Wang, MD, MHS, MSc, FAHA, FACC
Associate Professor of Medicine in Cardiology
Creative Educational Concepts is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-18-008-H01-P).
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Upon completion of a CE request form, statements of credit for physicians and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A com¬mercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with infor¬mation that might be of potential importance to their evaluation of a presentation.
Adrienne Matson, PharmD, BCPS – has no relevant financial relationships to disclose in relation to the content of this activity.
Content Development Faculty
Tracy Y. Wang, MD, MHS, MSc – has disclosed that she is a consultant for Gilead, Merck, and Sanofi and receives grant/research to her institute, Duke Clinical Research Institute, from AstraZeneca, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Lilly, Gilead Sciences, Novartis, Pfizer, and Regeneron, Dr. Wang herself has received grant/research support from AstraZeneca, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, Lilly, Novartis, Pfizer, and Regeneron.
Tracy E. Macaulay, PharmD, BCPS (AQ Cardiology) – has no relevant financial relationships to disclose in relation to the content of this activity.
Kim Newlin, RN, CNS, NP-C, FPCNA – has no relevant financial relationships to disclose in relation to the content of this activity.
Lorrel E. Brown, MD – has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN – has no relevant financial relationships to disclose in relation to the content of this activity.
Danielle Blais, PharmD, BCPS – has no relevant financial relationships to disclose in relation to the content of this activity.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.
COURSE VIEWING REQUIREMENTS
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Click here for the downloadable PDF: Updates in ACS Management